PrEP Check

Monitoring panel for individuals on HIV pre-exposure prophylaxis (PrEP), combining HIV and syphilis laboratory tests with chlamydia and gonorrhea screening, kidney function markers, and a PrEP-specific consultation. Recommended every three months for active PrEP users per German-Austrian PrEP guidelines.

Pre-exposure prophylaxis with tenofovir-based regimens requires regular monitoring to ensure the medication remains safe and the user has not seroconverted. The PrEP Check at Checkpoint München follows the German-Austrian guideline schedule, designed for quarterly visits that cover both HIV surveillance and the key safety parameters of the medication. HIV laboratory testing confirms ongoing seronegative status — a prerequisite for continued PrEP prescribing, since tenofovir monotherapy in an undiagnosed HIV-positive individual risks resistance development. Syphilis laboratory testing screens for a co-infection that PrEP does not protect against and that can facilitate HIV transmission if PrEP is discontinued. Chlamydia and gonorrhea smears cover the bacterial STIs most commonly seen in PrEP-using populations. Kidney function monitoring is the critical safety component. Tenofovir disoproxil fumarate (TDF) can affect renal tubular function in a minority of users, and creatinine-based estimated glomerular filtration rate tracking catches early changes before they become clinically significant. The PrEP consultation reviews adherence patterns, side effects, sexual health changes, and whether the current regimen and dosing schedule remain appropriate for the patient's risk profile.